Amgen ovarian cancer drug fails to improve overall survival

(Reuters) - Amgen Inc said its experimental ovarian cancer drug did not show statistically significant improvement in overall survival rate in a late-stage trial. Patients given the drug, trebananib, along with a chemotherapy agent paclitaxel, experienced overall survival of 19.3 months, compared with 18.3 months for the placebo group. Statistically significant improvement in overall survival was the secondary goal of the trial. The trial, TRINOVA-1, is the first of three late-stage studies to evaluate safety and effectiveness of the drug in ovarian cancer patients. ...



via Health News Headlines - Yahoo News http://ift.tt/1scUjdy